Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Palatin Technologies, a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics, has reported revenues of $674,957 for the fourth quarter ended 30 June 2010, compared to $4.23m for the comparable period in 2009.
Subscribe to our email newsletter
The company has posted a net loss of $4.24m for the fourth quarter 2010, or $0.40 loss per diluted share, compared to net loss of $200,530, or $0.02loss per diluted share, for the comparable period in 2009.
For the full year ended 30 June 2010, the company has posted revenue of $14.18m for the 12 months, compared to $11.35m for the year ago period.
Palatin has reported a net loss of $1.79m, or $0.18 per diluted share, compared to $4.8m, or $0.56 loss per diluted share, for the year ago period.